logo
Twitter
Discord
Email
logo
Artivion, Inc.

Artivion, Inc.

NYSE•AORT
CEO: Mr. James Patrick Mackin
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 1993-02-12
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
Contact Information
1655 Roberts Boulevard N.W., Kennesaw, GA, 30144, United States
770-419-3355
artivion.com
Market Cap
$2.19B
P/E (TTM)
-239.3
36.4
Dividend Yield
--
52W High
$48.25
52W Low
$21.97
52W Range
93%
Rank64Top 85.8%
2.1
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.1 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q3 2025 Data

Revenue

$113.39M+18.39%
4-Quarter Trend

EPS

$0.14-356.41%
4-Quarter Trend

FCF

$15.90M+103.47%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Quarterly Revenue Growth Strong Total revenues reached $113.4M for the three months ended September 30, 2025, marking an 18% increase.
Net Income Rebounds Significantly Net income was $6.5M for the quarter, successfully reversing the prior year loss of $(2.3)M.
Operating Cash Flow Increased Net cash provided by operating activities was $20.3M for nine months, an $8.2M increase year-over-year.
Equity Position Strengthened Total stockholders' equity grew to $438.7M as of September 30, 2025, up from $276.2M at year-end 2024.

Risk Factors

Contingent Liability Exposure Ascyrus contingent consideration liability stands at $55.3M, with valuation changes impacting G&A expenses quarterly.
Supply Chain Single Source Reliance on single suppliers for key components like BioGlue and stent graft systems creates disruption risk.
Regulatory Transition Hurdles MDR transition delays and potential CryoValve SGPV reclassification threaten EU market access and supply continuity.
Debt Covenants Limit Flexibility Indebtedness agreements impose financial covenants restricting new debt, asset sales, and dividend payments.

Outlook

Credit Facility Restructuring Complete Second Amendment extended maturity to January 2031, adding $150.0M New Delayed Draw Term Loan Facility.
Interest Expense Reduced Settled Convertible Senior Notes in 2025, leading to lower interest expense recognized in current periods.
Liquidity Forecast Adequate Expect operating cash flow and available credit facilities to cover all obligations over the next twelve months.
PerClot Milestone Achieved Recorded $3.5M pre-tax gain in Q3 2025 upon Baxter achieving cumulative worldwide sales milestone for PerClot.

Peer Comparison

Revenue (TTM)

Aveanna Healthcare Holdings Inc.AVAH
$2.29B
+15.5%
National HealthCare CorporationNHC
$1.50B
+22.1%
LifeStance Health Group, Inc.LFST
$1.37B
+13.4%

Gross Margin (Latest Quarter)

LeMaitre Vascular, Inc.LMAT
75.3%
+7.5pp
Artivion, Inc.AORT
65.6%
+1.9pp
PROCEPT BioRobotics CorporationPRCT
64.8%
+1.6pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
VERA$3.43B-15.7-46.7%13.4%
ATEC$3.11B-20.5-10368.8%75.1%
LFST$2.77B-302.6-0.6%22.0%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
5.2%
Steady Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
75%
Volatile Cash Flow

Research & Insights

Next earnings:Feb 23, 2026
|
EPS:$0.14
|
Revenue:-
Reports
All Years
  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 7, 2025|
    Revenue: $113.39M+18.4%
    |
    EPS: $0.14-356.4%
    Beat
  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 8, 2025|
    Revenue: $112.97M+15.3%
    |
    EPS: $0.03-159.6%
    Beat
  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 6, 2025|
    Revenue: $98.98M+1.6%
    |
    EPS: $-0.01-106.6%
    Beat
  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 28, 2025|
    Revenue: $388.54M+9.8%
    |
    EPS: $-0.32+57.3%
    Miss
  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 8, 2024|
    Revenue: $95.78M+9.0%
    |
    EPS: $-0.05-77.3%
    Beat
  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 9, 2024|
    Revenue: $98.02M+9.8%
    |
    EPS: $-0.05-38.8%
    Beat
  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 7, 2024|
    Revenue: $97.43M+17.1%
    |
    EPS: $0.18-154.5%
    Beat
  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 23, 2024|
    Revenue: $354.00M+12.8%
    |
    EPS: $-0.75-56.3%
    Miss